Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5674900 | 0.86 | POLB (0.52) | POLBHCAR2HTTALOX15 | |
| SCHEMBL2907354 | 0.81 | POLB (0.43) | POLBHCAR2 | |
| SCHEMBL28481352 | 0.81 | POLB (0.46) | POLBHCAR2 | |
| SCHEMBL21463360 | 0.80 | RAF1 (0.42) | — | |
| SCHEMBL27689512 | 0.80 | POLB (0.46) | POLBHCAR2 | |
| SCHEMBL12736324 | 0.78 | LMNA (0.53) | POLBHCAR2 | |
| SCHEMBL26698318 | 0.78 | CYP3A4 (0.53) | POLB | |
| SCHEMBL26698288 | 0.78 | ALDH1A1 (0.54) | — | |
| SCHEMBL28076602 | 0.78 | POLB (0.40) | POLBHCAR2 | |
| SCHEMBL27707795 | 0.78 | POLB (0.43) | POLBHCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103282364-B | Imidazo [4, 5 -] quinolin- 2 -one compound and its use as pi3 kinase / MTOR dual inhibitor | LILLY CO ELI | 2015-06-17 | — | — | CN | disclosed |
| CN-102753535-B | Quinazolines as Potassium Channel Inhibitors | BRISTOL MYERS SQUIBB CO | 2015-03-25 | — | — | CN | disclosed |
| CN-102459247-B | benzoxazolone derivatives as aldosterone synthase inhibitors | NOVARTIS AG | 2014-09-17 | — | — | CN | disclosed |
| CN-102356068-B | 2,3-diaryl- or heteroaryl-substituted 1,1,1-trifluoro-2-hydroxypropyl compounds | HOFFMANN LA ROCHE | 2014-04-23 | — | — | CN | disclosed |
| CN-101541785-B | Substituted dihydropyrazolones and use thereof as HIF-prolyl-4 -hydroxylase inhibitors | BAYER IP GMBH | 2014-03-12 | — | — | CN | disclosed |
| CN-103282364-A | Imidazo [4, 5 -] quinolin- 2 -one compound and its use as pi3 kinase / MTOR dual inhibitor | LILLY CO ELI | 2013-09-04 | — | — | CN | disclosed |
| CN-101798298-B | Imidazole derivatives | HOFFMANN LA ROCHE | 2013-01-09 | — | — | CN | disclosed |
| US-8352193-B2 | Methods for deriving a cumulative ranking | TARGET DISCOVERY, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| CN-102858745-A | Acylamino-substituted cyclic carboxylic acid derivatives and their use as medicaments | SANOFI AVENTIS | 2013-01-02 | — | — | CN | disclosed |
| CN-102753535-A | Quinazolines as Potassium Channel Inhibitors | BRISTOL MYERS SQUIBB CO | 2012-10-24 | — | — | CN | disclosed |
| US-20020103164-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | ADOLOR CORPORATION | 2002-08-01 | — | — | US | disclosed |
| US-6391910-B1 | OPIOID ANTAGONIST; ANALGESIC | ADOLOR CORPORATION | 2002-05-21 | — | — | US | disclosed |
| US-20020013296-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | ADOLOR CORPORATION | 2002-01-31 | — | — | US | disclosed |
| US-6303611-B1 | FOR THERAPY OF HYPERALGESIS | ADOLOR CORPORATION | 2001-10-16 | — | — | US | disclosed |
| CN-1312800-A | Therapeutic biaryl derivatives | GLAXO GROUP LTD (GB) | 2001-09-12 | — | — | CN | disclosed |
| EP-1112252-A1 | KAPPA AGONIST COMPOUNDS AND PHARMACEUTICAL FORMULATIONS THEREOF | Adolor Corporation (US) | 2001-07-04 | — | — | EP | disclosed |
| US-6239154-B1 | ARYLACETAMIDES, AGONISTS AT KAPPA OPIOID RECEPTORS. | ADOLOR CORPORATION | 2001-05-29 | — | — | US | disclosed |
| US-6057323-A | PIPERAZINE DERIVATIVES | ADOLOR CORPORATION (US) | 2000-05-02 | — | — | US | disclosed |
| US-6054445-A | KAPPA OPIOID AGONIST ACTIVITY; ANALGESICS AND ANTI-PRURITIC AGENTS | ADOLOR CORPORATION (US) | 2000-04-25 | — | — | US | disclosed |
| WO-2000014065-A1 | KAPPA AGONIST COMPOUNDS AND PHARMACEUTICAL FORMULATIONS THEREOF | ADOLOR CORPORATION (US) | 2000-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103164-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | OPRK1, OPRD1, HRH4 | POLB 2725/4885HCAR2 185/4885HTT 4791/4885 |
| US-20020013296-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | OPRK1, OPRD1, HRH4 | POLB 2725/4885HCAR2 185/4885HTT 4791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.